Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri

Edanur Yeşil

Research Article

Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri

Year 2022, Volume: 15 Issue: (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, 73 - 80, 30.06.2022

Edanur Yeşil

Abstract

İntravenöz immünglobulin (İVİG) dünyada en yaygın kullanılan plazma ürünüdür. Antikorlar içinde IgG immün sistemin doğal ve spesifik olan tek modülatör molekülüdür. İVİG çocukluk çağında düşük dozda yerine koyma, yüksek dozda da antienflamatuar veya immunmodulatuar etkileri nedeniyle kullanılmaktadır.

Keywords

Akılcı, ilaç, çocuk

References

1. Camcıoğlu, Y. İmmünoglobulin Tedavisi. Çocuk Enfeksiyon Dergisi. 2009; 3:2.
2. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008 Nov;28(4):737-64, viii. doi: 10.1016/j.iac.2008.06.004. PMID: 18940572.
3. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017 Mar;139(3S):S1-S46. doi: 10.1016/j.jaci.2016.09.023. Epub 2016 Dec 29. PMID: 28041678.
4. Lünemann JD, Quast I, Dalakas MC. Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics. 2016 Jan;13(1):34-46. doi: 10.1007/s13311-015-0391-5. PMID: 26400261; PMCID: PMC4720677.
5. Balch A, Wilkes J, Thorell E, et al. Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals. Int Immunopharmacol. 2019 Nov;76:105868. doi: 10.1016/j.intimp.2019.105868. Epub 2019 Sep 2. PMID: 31487613.
6. Okubo Y, Michihata N, Morisaki N, et al. Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia. Int J Hematol. 2018 Jan;107(1):75-82. doi: 10.1007/s12185-017-2322-1. Epub 2017 Aug 28. PMID: 28849369.
7. Yen CY, Hung MC, Wong YC, et al. Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis. Sci Rep. 2019 Jul 18;9(1):10459. doi: 10.1038/s41598-019-46888-0. PMID: 31320679; PMCID: PMC6639391.
8. Martinez V, Cohen P, Pagnoux C,et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008 Jan;58(1):308-17. doi: 10.1002/art.23147. PMID: 18163506.
9. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. Arch Dis Child. 1995 Jan;72(1):25-8. doi: 10.1136/adc.72.1.25. PMID: 7717731; PMCID: PMC1510958.
10. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;2003(4):CD004000. doi: 10.1002/14651858.CD004000. PMID: 14584002; PMCID: PMC6544780.
11. Lo MS, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018 Jan;21(1):64-69. doi: 10.1111/1756-185X.13220. Epub 2017 Dec 5. PMID: 29205910.
12. Rodriguez MM, Wagner-Weiner L. Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. Pediatr Ann. 2017 Jan 1;46(1):e19-e24. doi: 10.3928/19382359-20161214-01. PMID: 28079914.
13. Tangye SG, Al-Herz W, Bousfiha A,et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020 Jan;40(1):24-64. doi: 10.1007/s10875-019-00737-x. Epub 2020 Jan 17. Erratum in: J Clin Immunol. 2020 Feb 22; PMID: 31953710; PMCID: PMC7082301.
14. Sundin M, Remberger M, Lindqvist H, et al. Hypogammaglobulinemia in children after allogeneic hematopoietic stem cell transplantation: a cytokine mediated immunoglobulin isotype class switch arrest? Pediatr Blood Cancer. 2015 May;62(5):890-6. doi: 10.1002/pbc.25409. Epub 2015 Jan 26. PMID: 25623620.
15. INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial. BMC Pregnancy Childbirth. 2008 Dec 8;8:52. doi: 10.1186/1471-2393-8-52. PMID: 19063731; PMCID: PMC2626572.
16. Jarczak D, Kluge S, Nierhaus A. Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View. Int J Mol Sci. 2020 Aug 3;21(15):5543. doi: 10.3390/ijms21155543. PMID: 32756325; PMCID: PMC7432410.
17. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020 Feb;46(Suppl 1):10-67. doi: 10.1007/s00134-019-05878-6. PMID: 32030529; PMCID: PMC7095013.
18. Lexicomp. Immune globulin (Intravenous, subcutaneous, and intramuscular): Drug information. www.uptodate.com. Erişim Tarihi: Mart 2022.
19. Chopra Sanjiv. Hepatitis A virus infection: Treatment and prevention. www.uptodate.com. Erişim Tarihi: Mart 2022.
20. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021 Apr;73(4):e13-e29. doi: 10.1002/art.41616. Epub 2021 Feb 15. PMID: 33277976; PMCID: PMC8559788.
21. Klinik Pratikte İVİG Tedavisi. Editör Devrim Bozkurt. Palme Yayınları. 2021.
22. Porritt RA, Paschold L, Rivas MN, et al. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J Clin Invest. 2021 May 17;131(10):e146614. doi: 10.1172/JCI146614. PMID: 33705359; PMCID: PMC8121516.
23. Brodin P. SARS-CoV-2 infections in children: Understanding diverse outcomes. Immunity. 2022 Feb 8;55(2):201-209. doi: 10.1016/j.immuni.2022.01.014. Epub 2022 Jan 20. PMID: 35093190; PMCID: PMC8769938.
24. Yonker LM, Gilboa T, Ogata AF,et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. 2021 Jul 15;131(14):e149633. doi: 10.1172/JCI149633. PMID: 34032635; PMCID: PMC8279585.

Year 2022, Volume: 15 Issue: (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, 73 - 80, 30.06.2022

Edanur Yeşil

Abstract

References

1. Camcıoğlu, Y. İmmünoglobulin Tedavisi. Çocuk Enfeksiyon Dergisi. 2009; 3:2.
2. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am. 2008 Nov;28(4):737-64, viii. doi: 10.1016/j.iac.2008.06.004. PMID: 18940572.
3. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017 Mar;139(3S):S1-S46. doi: 10.1016/j.jaci.2016.09.023. Epub 2016 Dec 29. PMID: 28041678.
4. Lünemann JD, Quast I, Dalakas MC. Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics. 2016 Jan;13(1):34-46. doi: 10.1007/s13311-015-0391-5. PMID: 26400261; PMCID: PMC4720677.
5. Balch A, Wilkes J, Thorell E, et al. Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals. Int Immunopharmacol. 2019 Nov;76:105868. doi: 10.1016/j.intimp.2019.105868. Epub 2019 Sep 2. PMID: 31487613.
6. Okubo Y, Michihata N, Morisaki N, et al. Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia. Int J Hematol. 2018 Jan;107(1):75-82. doi: 10.1007/s12185-017-2322-1. Epub 2017 Aug 28. PMID: 28849369.
7. Yen CY, Hung MC, Wong YC, et al. Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis. Sci Rep. 2019 Jul 18;9(1):10459. doi: 10.1038/s41598-019-46888-0. PMID: 31320679; PMCID: PMC6639391.
8. Martinez V, Cohen P, Pagnoux C,et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008 Jan;58(1):308-17. doi: 10.1002/art.23147. PMID: 18163506.
9. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases. Arch Dis Child. 1995 Jan;72(1):25-8. doi: 10.1136/adc.72.1.25. PMID: 7717731; PMCID: PMC1510958.
10. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;2003(4):CD004000. doi: 10.1002/14651858.CD004000. PMID: 14584002; PMCID: PMC6544780.
11. Lo MS, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018 Jan;21(1):64-69. doi: 10.1111/1756-185X.13220. Epub 2017 Dec 5. PMID: 29205910.
12. Rodriguez MM, Wagner-Weiner L. Intravenous Immunoglobulin in Pediatric Rheumatology: When to Use It and What Is the Evidence. Pediatr Ann. 2017 Jan 1;46(1):e19-e24. doi: 10.3928/19382359-20161214-01. PMID: 28079914.
13. Tangye SG, Al-Herz W, Bousfiha A,et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020 Jan;40(1):24-64. doi: 10.1007/s10875-019-00737-x. Epub 2020 Jan 17. Erratum in: J Clin Immunol. 2020 Feb 22; PMID: 31953710; PMCID: PMC7082301.
14. Sundin M, Remberger M, Lindqvist H, et al. Hypogammaglobulinemia in children after allogeneic hematopoietic stem cell transplantation: a cytokine mediated immunoglobulin isotype class switch arrest? Pediatr Blood Cancer. 2015 May;62(5):890-6. doi: 10.1002/pbc.25409. Epub 2015 Jan 26. PMID: 25623620.
15. INIS Study Collaborative Group. The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial. BMC Pregnancy Childbirth. 2008 Dec 8;8:52. doi: 10.1186/1471-2393-8-52. PMID: 19063731; PMCID: PMC2626572.
16. Jarczak D, Kluge S, Nierhaus A. Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View. Int J Mol Sci. 2020 Aug 3;21(15):5543. doi: 10.3390/ijms21155543. PMID: 32756325; PMCID: PMC7432410.
17. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020 Feb;46(Suppl 1):10-67. doi: 10.1007/s00134-019-05878-6. PMID: 32030529; PMCID: PMC7095013.
18. Lexicomp. Immune globulin (Intravenous, subcutaneous, and intramuscular): Drug information. www.uptodate.com. Erişim Tarihi: Mart 2022.
19. Chopra Sanjiv. Hepatitis A virus infection: Treatment and prevention. www.uptodate.com. Erişim Tarihi: Mart 2022.
20. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021 Apr;73(4):e13-e29. doi: 10.1002/art.41616. Epub 2021 Feb 15. PMID: 33277976; PMCID: PMC8559788.
21. Klinik Pratikte İVİG Tedavisi. Editör Devrim Bozkurt. Palme Yayınları. 2021.
22. Porritt RA, Paschold L, Rivas MN, et al. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J Clin Invest. 2021 May 17;131(10):e146614. doi: 10.1172/JCI146614. PMID: 33705359; PMCID: PMC8121516.
23. Brodin P. SARS-CoV-2 infections in children: Understanding diverse outcomes. Immunity. 2022 Feb 8;55(2):201-209. doi: 10.1016/j.immuni.2022.01.014. Epub 2022 Jan 20. PMID: 35093190; PMCID: PMC8769938.
24. Yonker LM, Gilboa T, Ogata AF,et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. 2021 Jul 15;131(14):e149633. doi: 10.1172/JCI149633. PMID: 34032635; PMCID: PMC8279585.

There are 24 citations in total.

Details

Primary Language	Turkish
Subjects	Health Care Administration
Journal Section	Konuşmacı Metinleri
Authors	Edanur Yeşil This is me
Publication Date	June 30, 2022
Submission Date	March 26, 2022
Acceptance Date	March 26, 2022
Published in Issue	Year 2022 Volume: 15 Issue: (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı

Cite

APA	Yeşil, E. (2022). Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri. Mersin Üniversitesi Sağlık Bilimleri Dergisi, 15((Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı), 73-80.
AMA	Yeşil E. Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri. Mersin Univ Saglık Bilim derg. June 2022;15((Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı):73-80.
Chicago	Yeşil, Edanur. “Akılcı Ilaç kullanımı: Çocuklarda İVİG kullanım Ilkeleri”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 15, no. (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı (June 2022): 73-80.
EndNote	Yeşil E (June 1, 2022) Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri. Mersin Üniversitesi Sağlık Bilimleri Dergisi 15 (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı 73–80.
IEEE	E. Yeşil, “Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri”, Mersin Univ Saglık Bilim derg, vol. 15, no. (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, pp. 73–80, 2022.
ISNAD	Yeşil, Edanur. “Akılcı Ilaç kullanımı: Çocuklarda İVİG kullanım Ilkeleri”. Mersin Üniversitesi Sağlık Bilimleri Dergisi 15/(Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı (June 2022), 73-80.
JAMA	Yeşil E. Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri. Mersin Univ Saglık Bilim derg. 2022;15:73–80.
MLA	Yeşil, Edanur. “Akılcı Ilaç kullanımı: Çocuklarda İVİG kullanım Ilkeleri”. Mersin Üniversitesi Sağlık Bilimleri Dergisi, vol. 15, no. (Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı, 2022, pp. 73-80.
Vancouver	Yeşil E. Akılcı ilaç kullanımı: Çocuklarda İVİG kullanım ilkeleri. Mersin Univ Saglık Bilim derg. 2022;15((Özel Sayı-1) 21. Mersin Pediatri Günleri Bildiri Kitabı):73-80.

Download Cover Image

Article Files

Full Text

MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.

Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.

Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.

Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.

Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.

Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.

15456 15458 15459

This work is licensed with Attribution-NonCommercial 4.0 International.